2
|
Kakarla R, Liu J, Naduthambi D, Chang W, Mosley RT, Bao D, Steuer HMM, Keilman M, Bansal S, Lam AM, Seibel W, Neilson S, Furman PA, Sofia MJ. Discovery of a novel class of potent HCV NS4B inhibitors: SAR studies on piperazinone derivatives. J Med Chem 2014; 57:2136-60. [PMID: 24476391 DOI: 10.1021/jm4012643] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
HTS screening identified compound 2a (piperazinone derivative) as a low micromolar HCV genotype 1 (GT-1) inhibitor. Resistance mapping studies suggested that this piperazinone chemotype targets the HCV nonstructural protein NS4B. Extensive SAR studies were performed around 2a and the amide function and the C-3/C-6 cis stereochemistry of the piperazinone core were essential for HCV activity. A 10-fold increase in GT-1 potency was observed when the chiral phenylcyclopropyl amide side chain of 2a was replaced with p-fluorophenylisoxazole-carbonyl moiety (67). Replacing the C-6 nonpolar hydrophobic moiety of 67 with a phenyl moiety (95) did not diminish the GT-1 potency. A heterocyclic thiophene moiety (103) and an isoxazole moiety (108) were incorporated as isosteric replacements for the C-6 phenyl moiety (95), resulting in significant improvement in GT-1b and 1a potency. However, the piperazonone class of compounds lacks GT-2 activity and, consequently, were not pursued further into development.
Collapse
Affiliation(s)
- Ramesh Kakarla
- Pharmasset, Inc. 303A College Road East, Princeton, New Jersey 08540, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Jiang Y, Andrews SW, Condroski KR, Buckman B, Serebryany V, Wenglowsky S, Kennedy AL, Madduru MR, Wang B, Lyon M, Doherty GA, Woodard BT, Lemieux C, Geck Do M, Zhang H, Ballard J, Vigers G, Brandhuber BJ, Stengel P, Josey JA, Beigelman L, Blatt L, Seiwert SD. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. J Med Chem 2013; 57:1753-69. [PMID: 23672640 DOI: 10.1021/jm400164c] [Citation(s) in RCA: 104] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response pathway through direct cleavage of key proteins in the human innate immune system. Through structure-based drug design and optimization, macrocyclic peptidomimetic molecules bearing both a lipophilic P2 isoindoline carbamate and a P1/P1' acylsulfonamide/acylsulfamide carboxylic acid bioisostere were prepared that possessed subnanomolar potency against the NS3 protease in a subgenomic replicon-based cellular assay (Huh-7). Danoprevir (compound 49) was selected as the clinical development candidate for its favorable potency profile across multiple HCV genotypes and key mutant strains and for its good in vitro ADME profiles and in vivo target tissue (liver) exposures across multiple animal species. X-ray crystallographic studies elucidated several key features in the binding of danoprevir to HCV NS3 protease and proved invaluable to our iterative structure-based design strategy.
Collapse
Affiliation(s)
- Yutong Jiang
- Array BioPharma , 3200 Walnut Street, Boulder, Colorado 80301, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Miller JF, Chong PY, Shotwell JB, Catalano JG, Tai VWF, Fang J, Banka AL, Roberts CD, Youngman M, Zhang H, Xiong Z, Mathis A, Pouliot JJ, Hamatake RK, Price DJ, Seal JW, Stroup LL, Creech KL, Carballo LH, Todd D, Spaltenstein A, Furst S, Hong Z, Peat AJ. Hepatitis C Replication Inhibitors That Target the Viral NS4B Protein. J Med Chem 2013; 57:2107-20. [DOI: 10.1021/jm400125h] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- John F. Miller
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Pek Y. Chong
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - J. Brad Shotwell
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - John G. Catalano
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Vincent W.-F. Tai
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Jing Fang
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Anna L. Banka
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Christopher D. Roberts
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Michael Youngman
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Huichang Zhang
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Zhiping Xiong
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Amanda Mathis
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Jeffery J. Pouliot
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Robert K. Hamatake
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Daniel J. Price
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - John W. Seal
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Lisa L. Stroup
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Katrina L. Creech
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Luz H. Carballo
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Dan Todd
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Andrew Spaltenstein
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Sylvia Furst
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Zhi Hong
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| | - Andrew J. Peat
- GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park,
North Carolina 27709, United States
| |
Collapse
|
5
|
St. Laurent DR, Serrano-Wu MH, Belema M, Ding M, Fang H, Gao M, Goodrich JT, Krause RG, Lemm JA, Liu M, Lopez OD, Nguyen VN, Nower PT, O’Boyle DR, Pearce BC, Romine JL, Valera L, Sun JH, Wang YK, Yang F, Yang X, Meanwell NA, Snyder LB. HCV NS5A Replication Complex Inhibitors. Part 4.1 Optimization for Genotype 1a Replicon Inhibitory Activity. J Med Chem 2013; 57:1976-94. [DOI: 10.1021/jm301796k] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Denis R. St. Laurent
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Michael H. Serrano-Wu
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Makonen Belema
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Min Ding
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Hua Fang
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Min Gao
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Jason T. Goodrich
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Rudolph G. Krause
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Julie A. Lemm
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Mengping Liu
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Omar D. Lopez
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Van N. Nguyen
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Peter T. Nower
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Donald R. O’Boyle
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Bradley C. Pearce
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Jeffrey L. Romine
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Lourdes Valera
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Jin-Hua Sun
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Ying-Kai Wang
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Fukang Yang
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Xuejie Yang
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Nicholas A. Meanwell
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Lawrence B. Snyder
- Departments of †Medicinal Chemistry, ‡Virology, and §Computer-Aided Drug Design, Bristol-Myers Squibb Research and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| |
Collapse
|